Corient Capital Partners, LLC Alaunos Therapeutics, Inc. Transaction History

Corient Capital Partners, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$0.62 - $1.17 $6,741 - $12,722	-10,874 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$1.09 - $1.89 $38,970 - $67,573	-35,753 Reduced 76.68%	10,874 $12,000
Q3 2021 Nov 16, 2021	SELL	$1.44 - $2.73 $102 - $193	-71 Reduced 0.15%	46,627 $85,000
Q2 2021 Aug 16, 2021	BUY	$2.63 - $3.67 $37,977 - $52,994	14,440 Added 44.76%	46,698 $123,000
Q4 2020 Feb 12, 2021	BUY	$2.09 - $3.09 $67,419 - $99,677	32,258 New	32,258 $82,000

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $443M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Corient Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Corient Capital Partners, LLC with notifications on news.